Imatinib mesylate

References

Citations

1. National Comprehensive Cancer Network (2006). Chronic myelogenous leukemia, version 1.2006. Available online: http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf.

2. Lichtman MA, Liesveld JL (2006). Chronic myelogenous leukemia and related disorders. In MA Lichtman et al., eds., Williams Hematology, 7th ed., pp. 1237–1294. New York: McGraw-Hill.

3. Druker BJ, et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23): 2408–2417.

4. Kerkelä R, et al (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12(8): 908–916.

Author:	Bets Davis, MFA	Last Updated: November 26, 2008
Medical Review:	Anne C. Poinier, MD - Internal Medicine Brian Leber, MDCM, FRCPC - Hematology
© 1995-2010 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.